U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07163650) titled 'Randomized Controlled Trial Evaluating Anti-Obesity Medications 6 Months After Metabolic Surgery' on Sept. 01.
Brief Summary: This clinical trial aims to evaluate the weight-loss efficacy and safety of efsubaglutide alfa in patients who remain obese 6 months after metabolic surgery.
Study Start Date: Sept. 01
Study Type: INTERVENTIONAL
Condition:
Obesity
Weight Loss
GLP-1 Receptor Agonist
Metabolic Surgery
Intervention:
DRUG: Efsubaglutide Alfa Injection
Efsubaglutide Alfa was injected daily in the morning before meals Subcutaneous injection at a dose of 1 mg/week in the first two weeks, increased to 3 mg/week in week 3, inc...